Paper Details

  1. Home
  2. Paper Details

Increased conventional chemotherapy does not improve survival in multiple myeloma: long-term results of two PETHEMA trials including 914 patients.

Author: AlcaláA, BesalduchJ, BessesC, BladéJ, BrunetS, CarbonellF, CarneroM, CondeE, EscuderoM L, EstapéJ, EsteveJ, Fernández-CalvoJ, FontL, FontanillasM, García-CondeJ, GardellaS, Hernández-MartínJ, MaldonadoJ, MartíJ M, MontserratE, MoroM J, OrtegaF, RiberaJ M, RozmanC, San MiguelJ F, TrujilloJ

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study compared different dose intensities of chemotherapy for multiple myeloma. The long-term outcomes of 914 patients from two randomized trials were analyzed. There was no significant difference in survival between conventional doses and higher doses of chemotherapy.
Paper Details　
Original Abstract of the Article :
Melphalan and prednisone (MP) has been the standard treatment for multiple myeloma (MM) for the last 30 years. Combination chemotherapy at conventional doses has not shown a significant prolongation of survival when compared to MP. There are few data comparing conventional chemotherapy at standard d...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1038/sj.thj.6200115

データ提供：米国国立医学図書館（NLM）

The Quest for Optimal Treatment in Multiple Myeloma: A Tale of Dose Intensity

This study delves into the challenging world of multiple myeloma (MM) treatment, examining the impact of dose intensity on patient survival. The researchers explored the effectiveness of different chemotherapy regimens in treating MM, seeking to identify the optimal approach for achieving the best outcomes. The researchers conducted a long-term analysis of data from two randomized clinical trials to evaluate the efficacy of different chemotherapy regimens in treating MM.

Dose Intensity and Survival in Multiple Myeloma: A Complex Relationship

The study found that increasing the dose intensity of chemotherapy did not result in significantly improved survival for patients with MM. These findings challenge the conventional belief that higher doses of chemotherapy are always superior. The study emphasizes the importance of carefully considering individual patient factors when determining the optimal treatment approach for MM.

Navigating the Complexities of Cancer Treatment

This study highlights the importance of carefully considering individual patient factors when making treatment decisions for MM. The findings suggest that a one-size-fits-all approach may not be the best strategy for this complex disease. This research underscores the need for individualized treatment plans tailored to each patient's specific needs and characteristics. It's like a camel navigating a desert – the optimal path may vary depending on the terrain and resources available.

Dr. Camel's Conclusion

This study is a valuable reminder that cancer treatment is a complex and evolving field. The researchers have made a significant contribution by challenging traditional assumptions about dose intensity in MM. Their findings underscore the importance of individualizing treatment plans based on patient characteristics and carefully considering the potential benefits and risks of different therapies.

Date :
  1. Date Completed 2002-06-13
  2. Date Revised 2019-11-05
Further Info :

Pubmed ID

11920260

DOI: Digital Object Identifier

10.1038/sj.thj.6200115

Related Literature

Article Analysis
・Effective treatment of multiple myeloma
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.